Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

NCT02826798 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: VBI-1501A 0.5 μg
DRUG: VBI-1501A 1.0 μg
DRUG: VBI-1501A 2.0 μg
DRUG: VBI-1501 1.0 μg
DRUG: Placebo

Sponsor

VBI Vaccines Inc.

Collaborators

[object Object]